• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Coty Strengthens Consumer Beauty Business With Senior Talent

    12/2/20 3:00:00 AM ET
    $JNJ
    $COTY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Package Goods/Cosmetics
    Consumer Discretionary
    Get the next $JNJ alert in real time by email

    NEW YORK--(BUSINESS WIRE)--Coty Inc. (NYSE: COTY), one of the world’s leading beauty companies and the global leader in fragrances, today announced two leaders to drive its Consumer Beauty organization. Stefano Curti will join the company as Chief Brands Officer, Consumer Beauty, while Alexis Vaganay will be promoted to Chief Commercial Officer, Consumer Beauty. The appointments come as CEO Sue Y. Nabi strengthens her leadership team, following the recent additions of Isabelle Bonfanti as Chief Commercial Officer, Luxury, and Jean-Denis Mariani as Chief Digital Officer.

    Stefano Curti joins Coty this week as Chief Brands Officer, Consumer Beauty and will be based in New York. Curti – who has a strong track record of brand building and channel expansions – will focus on strengthening the division’s brand equity, global positioning and innovation performance. He brings a wealth of senior international experience, having spent almost 30 years working in the beauty and health industry in the U.S., Europe and Latin America. Curti joins from Markwins Beauty Brands – the largest independent cosmetics company in the U.S., with established mass cosmetics brands including Physicians Formula, LORAC, Black Radiance and WetnWild – where he served as Global President. He spent 22 years at Johnson & Johnson, where he progressed through the marketing organization to the role of Global President Beauty and Baby divisions. During his time at J&J, Curti led iconic skin and personal care brands like Aveeno, Clean & Clear and Neutrogena, driving above-market sales growth and double-digit profit growth for the beauty portfolio.

    Coty also announced the promotion of Alexis Vaganay to Chief Commercial Officer, Consumer Beauty. Vaganay, who has more than 20 years’ experience in international sales and marketing, takes up his appointment this week and will be based in Coty’s Amsterdam headquarters. He will be responsible for leading Coty’s regions - in close collaboration with his Luxury counterpart - and developing Consumer Beauty’s commercial strategy to increase market share and grow revenues in color cosmetics, body care and consumer fragrances. Most recently, Vaganay was EVP, EMEA, following four years as General Manager of UK&I Luxury. Under his leadership, Coty UK&I was among the fastest growing luxury fragrance players. Prior to joining Coty in 2016, Vaganay worked at Unilever and Bic in a variety of global roles.

    Sue Y. Nabi, CEO of Coty, said, “My ambition from day one has been to quickly build a first-class leadership team. The appointment of these two leaders means we are now in great shape to re-position our portfolio of brands more clearly. Stefano’s track record and sector expertise makes him the right leader for our Consumer Beauty transformation. Alexis, likewise, is a proven leader within Coty and his deep knowledge of our business and brands makes him the perfect fit to accelerate our growth on all continents.”

    Nabi continued: “Consumer Beauty is a critical pillar of our business. In times of uncertainty, the consumer beauty industry has an essential mission: the place where people can access the latest trends and innovations, find the best quality at an accessible price and experience the diversity of all kinds of beauties. That’s why we are excited that Coty has found two beauty champions who will enable our portfolio of meaningful brands - which include COVERGIRL, Sally Hansen, Rimmel, Bourjois, adidas and David Beckham, to name a few - to truly thrive.”

    In October, Coty announced the appointment of Isabelle Bonfanti as Chief Commercial Officer, Luxury. She boasts more than 30 years’ experience in international brand development and transformation, including 17 years in L’Oréal’s Luxury division. Bonfanti was joined by Jean-Denis Mariani as Chief Digital Officer, who joined from Guerlain as Coty continues to generate record e-commerce sales across its portfolio.

    About Coty Inc.

    Coty is one of the world’s largest beauty companies with an iconic portfolio of brands across fragrance, color cosmetics, and skin and body care. Coty is the global leader in fragrance and number three in color cosmetics. Coty’s products are sold in over 150 countries around the world. Coty and its brands are committed to a range of social causes as well as seeking to minimize its impact on the environment. For additional information about Coty Inc., please visit www.coty.com.

    Get the next $JNJ alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $JNJ
    $COTY

    CompanyDatePrice TargetRatingAnalyst
    Coty Inc.
    $COTY
    11/25/2025$3.60Neutral
    Rothschild & Co Redburn
    Johnson & Johnson
    $JNJ
    11/13/2025$230.00Sector Outperform
    Scotiabank
    Johnson & Johnson
    $JNJ
    10/20/2025$203.00Neutral → Outperform
    Daiwa Securities
    Johnson & Johnson
    $JNJ
    10/3/2025$212.00Equal Weight → Overweight
    Wells Fargo
    Johnson & Johnson
    $JNJ
    9/23/2025$206.00Neutral → Buy
    Guggenheim
    Coty Inc.
    $COTY
    9/10/2025$5.05Buy → Hold
    Berenberg
    Coty Inc.
    $COTY
    8/22/2025$12.00 → $10.00Sector Perform
    RBC Capital Mkts
    Coty Inc.
    $COTY
    8/21/2025$4.25Buy → Neutral
    Citigroup
    More analyst ratings

    $JNJ
    $COTY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ballini Beatrice sold $55,300 worth of shares (7,000 units at $7.90) and bought $185,600 worth of shares (20,000 units at $9.28) (SEC Form 4)

    4 - COTY INC. (0001024305) (Issuer)

    11/18/25 7:44:01 PM ET
    $COTY
    Package Goods/Cosmetics
    Consumer Discretionary

    Chief Legal Officer Blazewicz Kristin bought $126,532 worth of shares (29,400 units at $4.30), increasing direct ownership by 4% to 829,142 units (SEC Form 4)

    4 - COTY INC. (0001024305) (Issuer)

    9/3/25 7:00:40 PM ET
    $COTY
    Package Goods/Cosmetics
    Consumer Discretionary

    Chief Financial Officer Mercier Laurent bought $61,017 worth of shares (15,500 units at $3.94), increasing direct ownership by 4% to 405,216 units (SEC Form 4)

    4 - COTY INC. (0001024305) (Issuer)

    8/28/25 6:30:00 PM ET
    $COTY
    Package Goods/Cosmetics
    Consumer Discretionary

    $JNJ
    $COTY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rothschild & Co Redburn initiated coverage on Coty with a new price target

    Rothschild & Co Redburn initiated coverage of Coty with a rating of Neutral and set a new price target of $3.60

    11/25/25 8:40:40 AM ET
    $COTY
    Package Goods/Cosmetics
    Consumer Discretionary

    Scotiabank initiated coverage on Johnson & Johnson with a new price target

    Scotiabank initiated coverage of Johnson & Johnson with a rating of Sector Outperform and set a new price target of $230.00

    11/13/25 9:14:21 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson upgraded by Daiwa Securities with a new price target

    Daiwa Securities upgraded Johnson & Johnson from Neutral to Outperform and set a new price target of $203.00

    10/20/25 8:00:27 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $COTY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*

    Expanded indication for AKEEGA® (niraparib and abiraterone acetate dual-action tablet) plus prednisone marks the first FDA-approved precision medicine combination treatment for patients with BRCA2-mutated mCSPC HORSHAM, Pa., Dec. 12, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for AKEEGA® (niraparib and abiraterone acetate dual-action tablet) plus prednisone for the treatment of patients with BRCA2-mutated metastatic castration-sensitive prostate cancer (mCSPC).1 Patients with BRCA mutations often have more aggressive forms of prostate cancer leading to poor prognosis, rep

    12/12/25 8:25:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson to Participate in the 44th Annual J.P. Morgan Healthcare Conference

    Johnson & Johnson (NYSE:JNJ) will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12th, 2026. Management will participate in a Fireside Chat at 11:15 a.m. Eastern Time. A live audio webcast of the presentation will be accessible through Johnson & Johnson's Investor Relations website at www.investor.jnj.com. An archived edition of the session will be available later that day. The audio webcast replay will be available approximately 48 hours after the webcast. View source version on businesswire.com: https://www.businesswire.com/news/home/20251208077091/en/ Media contact: [email protected] Investor contact: [email protected]

    12/8/25 4:25:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson's INLEXZO™ (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC

    New data from Cohort 4 of the SunRISe-1 study show more than 95 percent of patients remained progression free at one year, with more than 92 percent not undergoing bladder removal Patients with this type of bladder cancer have limited choices beyond radical cystectomy, highlighting the need for newer therapies for bladder preservation RARITAN, N.J., Dec. 5, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today that new data from the investigational Cohort 4 of the Phase 2b SunRISe-1 study show treatment with gemcitabine intravesical system resulted in high one-year disease-free survival (DFS), progression-free survival (PFS), and overall survival (OS) rates in patients with Bacil

    12/5/25 4:20:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $COTY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Woods Eugene A.

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    12/11/25 5:02:15 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Hewson Marillyn A

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    12/11/25 4:59:44 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Pinto Daniel E

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    12/11/25 4:58:40 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $COTY
    SEC Filings

    View All

    SEC Form 13F-HR filed by Johnson & Johnson

    13F-HR - JOHNSON & JOHNSON (0000200406) (Filer)

    11/13/25 3:25:42 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Coty Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - COTY INC. (0001024305) (Filer)

    11/12/25 4:10:00 PM ET
    $COTY
    Package Goods/Cosmetics
    Consumer Discretionary

    SEC Form 10-Q filed by Coty Inc.

    10-Q - COTY INC. (0001024305) (Filer)

    11/5/25 4:37:52 PM ET
    $COTY
    Package Goods/Cosmetics
    Consumer Discretionary

    $JNJ
    $COTY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    July 21, 2023 - FDA Roundup: July 21, 2023

    For Immediate Release: July 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA Center for Tobacco Products (CTP) announced that the center will host a virtual listening session on Aug. 22, 2023. During this listening session, CTP is requesting feedback on the development of a new 5-year strategic plan for the center, includin

    7/21/23 4:02:23 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    May 5, 2022 - Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals

    For Immediate Release: May 05, 2022 Today, the U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not

    5/5/22 4:51:11 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    August 18, 2021 - Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster Shots

    For Immediate Release: August 18, 2021 Today, public health and medical experts from the U.S. Department of Health and Human Services (HHS) released the following statement on the Administration’s plan for COVID-19 booster shots for the American people. The statement is attributable to Dr. Rochelle Walensky, Director of the Centers for Disease Control and Prevention (CDC); Dr. Janet Woodcock, Acting Commissione

    8/18/21 1:06:11 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $COTY
    Financials

    Live finance-specific insights

    View All

    Coty Reports In Line Q1 Results, with Q2 Sales Tracking Toward the More Favorable End of Prior Guidance; Expects a Return to Growth in 2H FY26

    BOSS Bottled Beyond Success and Fragrance Mist Expansion Reinforce Global Fragrance & Scenting Leadership Executional Improvements Driving Q1 U.S. Prestige Fragrance Sell-Out In Line with Market "All In to Win" Program Continues to Deliver Efficiency, Agility and Cost Discipline Building Performance Improvement Plan for Consumer Beauty While Progressing with Strategic Review Regulatory News: Coty Inc. (NYSE:COTY) (PARIS:COTY) ("Coty" or "the Company") today announced its results for the first quarter of fiscal year 2026, ended September 30, 2025. Coty delivered Q1 in line with expectations, with Q2 sales tracking toward the more favorable end of prior guidance. Coty's strengthening execut

    11/5/25 4:30:00 PM ET
    $COTY
    Package Goods/Cosmetics
    Consumer Discretionary

    Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2025

    Johnson & Johnson (NYSE:JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2025 of $1.30 per share on the company's common stock. The dividend is payable on December 9, 2025 to shareholders of record at the close of business on November 25, 2025. The ex-dividend date is November 25, 2025. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquel

    10/14/25 6:30:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson Announces Intent to Separate Its Orthopaedics Business

    Strengthens focus of Johnson & Johnson as an innovation powerhouse and accelerates the portfolio shift of its MedTech Segment to higher-growth and higher-margin markets Standalone orthopaedics business would operate as DePuy Synthes and be the largest, most comprehensive orthopaedics-focused company in the world Namal Nawana appointed to serve as Worldwide President of DePuy Synthes Johnson & Johnson (the "Company") (NYSE:JNJ) today announced the Company's intent to separate its Orthopaedics business to enhance the strategic and operational focus of each company and drive value for stakeholders. The intended separation would further strengthen the focus of Johnson & Johnson as an in

    10/14/25 6:21:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $COTY
    Leadership Updates

    Live Leadership Updates

    View All

    Vicarious Surgical Announces Appointment of Joseph Doherty as Chairman of The Board

    Vicarious Surgical Inc. (NYSE:RBOT, RBOT.WS)) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the appointment of Joseph Doherty as Chairman of the Company's Board of Directors (the "Board"). Mr. Doherty has served as a member of the Board since June 2025. "Since joining Vicarious Surgical, I've had the opportunity to work closely with Joe and greatly value his perspective," said Stephen From, Chief Executive Officer. "As Chairman of the Board, he brings a wealth of experience and thoughtful leadership that will serve the Company well. I look forward to partnering with him and the Board as we advance o

    9/25/25 4:15:00 PM ET
    $JNJ
    $RBOT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties

    Johnson & Johnson Elects John Morikis, Retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, to its Board of Directors

    Johnson & Johnson (NYSE:JNJ) announced today that John Morikis, retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, has been elected to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250908666514/en/John Morikis headshot "We are pleased to welcome John to our Company's Board of Directors," said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "He is a proven leader of a large multinational organization who possesses a strong understanding of global markets and complex supply chains. His unique perspective and ability to harness technology to driv

    9/8/25 6:17:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors

    Johnson & Johnson (NYSE:JNJ) announced today that Daniel Pinto, President, JPMorganChase, has been elected to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250610707025/en/ "We are thrilled to have Daniel join Johnson & Johnson's Board of Directors," said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "He is an exceptional leader with deep financial expertise and understanding of global capital markets. Daniel's unique perspective and wealth of experience will be a tremendous asset to Johnson & Johnson as we continue to invest in and advance the next generation of healthcare inno

    6/10/25 4:51:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $COTY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Johnson & Johnson

    SC 13G - JOHNSON & JOHNSON (0000200406) (Filed by)

    4/10/24 5:12:55 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Johnson & Johnson (Amendment)

    SC 13G/A - JOHNSON & JOHNSON (0000200406) (Subject)

    2/13/24 5:07:58 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Johnson & Johnson (Amendment)

    SC 13G/A - JOHNSON & JOHNSON (0000200406) (Subject)

    1/30/24 12:46:49 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care